HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays

Journal of Virological Methods

Volumn 146, Issue 1-2, 2007, Pages 61-73

  Van Baelen, Kurt ^a   Vandenbroucke, Ina ^a   Rondelez, Evelien ^a   Van Eygen, Veerle ^a   Vermeiren, Hans ^a   Stuyver, Lieven J ^a  

^a Virco BVBA   (Belgium)

Author keywords

Coreceptor; Envelope; Human immunodeficiency virus; Tropism

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENHANCED GREEN FLUORESCENT PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ALGORITHM; ARTICLE; CLONE; CONTROLLED STUDY; COST; EMBRYO; GENE SEQUENCE; GENOTYPE; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL POPULATION DYNAMICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SPECIES DIVERSITY; VIRUS CLASSIFICATION; VIRUS DETECTION; VIRUS ISOLATION;

ALGORITHMS; AMINO ACID SEQUENCE; GENOTYPE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHENOTYPE; PHYLOGENY; RECEPTORS, CCR5; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35548947372     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2007.06.003     Document Type: Article

References (46)

1. Beerenwinkel N., Sing T., Lengauer T., Rahnenfuhrer J., Roomp K., Savenkov I., Fischer R., Hoffmann D., Selbig J., Korn K., Walter H., Berg T., Braun P., Fatkenheuer G., Oette M., Rockstroh J., Kupfer B., Kaiser R., and Daumer M. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21 (2005) 3943-3950
2. Berger E.A., Doms R.W., Fenyo E.M., Korber B.T., Littman D.R., Moore J.P., Sattentau Q.J., Schuitemaker H., Sodroski J., and Weiss R.A. A new classification for HIV-1. Nature 391 (1998) 240
3. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
4. Boyd M.T., Simpson G.R., Cann A.J., Johnson M.A., and Weiss R.A. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J. Virol. 67 (1993) 3649-3652
5. Bozzette S.A., McCutchan J.A., Spector S.A., Wright B., and Richman D.D. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J. Infect. Dis. 168 (1993) 1374-1379
6. Brumme Z.L., Dong W.W., Yip B., Wynhoven B., Hoffman N.G., Swanstrom R., Jensen M.A., Mullins J.I., Hogg R.S., Montaner J.S., and Harrigan P.R. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. Aids 18 (2004) F1-F9
7. Brumme Z.L., Goodrich J., Mayer H.B., Brumme C.J., Henrick B.M., Wynhoven B., Asselin J.J., Cheung P.K., Hogg R.S., Montaner J.S., and Harrigan P.R. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. 192 (2005) 466-474
8. Carrillo A., and Ratner L. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J. Virol. 70 (1996) 1301-1309
9. Chen B.K., Feinberg M.B., and Baltimore D. The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J. Virol. 71 (1997) 5495-5504
10. Clevestig P., Pramanik L., Leitner T., and Ehrnst A. CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. J. Gen. Virol. 87 (2006) 607-612
11. Coakley E., Petropoulos C.J., and Whitcomb J.M. Assessing chemokine co-receptor usage in HIV. Curr. Opin. Infect. Dis. 18 (2005) 9-15
12. Connor R.I., Sheridan K.E., Ceradini D., Choe S., and Landau N.R. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185 (1997) 621-628
13. Crabb C. GlaxoSmithKline ends aplaviroc trials. Aids 20 (2006) 641
14. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., and Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
15. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., Cayanan C., Maddon P.J., Koup R.A., Moore J.P., and Paxton W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996) 667-673
16. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., Saag M.S., Goebel F.D., Rockstroh J.K., Dezube B.J., Jenkins T.M., Medhurst C., Sullivan J.F., Ridgway C., Abel S., James I.T., Youle M., and van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11 (2005) 1170-1172
17. Felsenstein J. PHYLIP (Phylogeny Inference Package) Version 3.5c (Distributed by the author) (1993), Department of Genetics, University of Washington, Seattle
18. Feng Y., Broder C.C., Kennedy P.E., and Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 (1996) 872-877
19. Fouchier R.A., Groenink M., Kootstra N.A., Tersmette M., Huisman H.G., Miedema F., and Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66 (1992) 3183-3187
20. Groenink M., Fouchier R.A., Broersen S., Baker C.H., Koot M., van't Wout A.B., Huisman H.G., Miedema F., Tersmette M., and Schuitemaker H. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260 (1993) 1513-1516
21. Jansson M., Backstrom E., Scarlatti G., Bjorndal A., Matsuda S., Rossi P., Albert J., and Wigzell H. Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 17 (2001) 1405-1414
22. Jensen M.A., and van 't Wout A.B. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev. 5 (2003) 104-112
23. Labrosse B., Labernardiere J.L., Dam E., Trouplin V., Skrabal K., Clavel F., and Mammano F. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J. Virol. 77 (2003) 1610-1613
24. Mayer, H., van der Ryst, E., Saag, M., Clotet, B., Fatkenheuer, G., Clumeck, N., Turner, K., Goodrich, J.M., 2006. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with Dual/Mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial.
25. Moore J.P., Kitchen S.G., Pugach P., and Zack J.A. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20 (2004) 111-126
26. Ogert R.A., Lee M.K., Ross W., Buckler-White A., Martin M.A., and Cho M.W. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J. Virol. 75 (2001) 5998-6006
27. Pillai S., Good B., Richman D., and Corbeil J. A new perspective on V3 phenotype prediction. AIDS Res. Hum. Retroviruses 19 (2003) 145-149
28. Pollakis G., Kang S., Kliphuis A., Chalaby M.I., Goudsmit J., and Paxton W.A. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 276 (2001) 13433-13441
29. Polzer S., Dittmar M.T., Schmitz H., Meyer B., Muller H., Krausslich H.G., and Schreiber M. Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1. Glycobiology 11 (2001) 11-19
30. Polzer S., Dittmar M.T., Schmitz H., and Schreiber M. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304 (2002) 70-80
31. Resch W., Hoffman N., and Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288 (2001) 51-62
32. Rizzuto C., and Sodroski J. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 16 (2000) 741-749
33. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., and Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280 (1998) 1949-1953
34. Roman F., Ammerlaan W., Plesseria J.M., Deroo S., Muller C.P., Arendt V., Schneider F., Hemmer R., and Schmit J.C. A new recombinant virus system for the study of HIV-1 entry and inhibition. J. Virol. Methods 131 (2006) 99-104
35. Scarlatti G., Tresoldi E., Bjorndal A., Fredriksson R., Colognesi C., Deng H.K., Malnati M.S., Plebani A., Siccardi A.G., Littman D.R., Fenyo E.M., and Lusso P. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3 (1997) 1259-1265
36. Schols D., Cleaes S., Hatse S., Princen K., Vermeire K., De Clercq E., Skerlj R., Bridger G., and Calandra G. Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist. Xth Conference on Retroviruses and Opportunistic Infections. Boston, USA (2003)
37. Schuitemaker H., Koot M., Kootstra N.A., Dercksen M.W., de Goede R.E., van Steenwijk R.P., Lange J.M., Schattenkerk J.K., Miedema F., and Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at 35 different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66 (1992) 1354-1360
38. Seibert C., and Sakmar T.P. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr. Pharm. Des. 10 (2004) 2041-2062
39. Sing T., Beerenwinkel N., and Lengauer T. Learning mixtures of localized rules by maximizing the area under the ROC curve. Proceedings of the 1st International Workshop on ROC Analysis in Artificial Intelligence (2004) 89-96
40. Sing, T., Harrigan, R., Beerenwinkel, N., Daumer, M., Kaiser, R., Low, A., Cheung, P.K., Lengauer, T., 2006. Immunologic markers improve genotypic prediction of HIV-1 coreceptor usage.
41. Smyth R.J., Yi Y., Singh A., and Collman R.G. Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J. Virol. 72 (1998) 4478-4484
42. Strizki J.M., Tremblay C., Xu S., Wojcik L., Wagner N., Gonsiorek W., Hipkin R.W., Chou C.C., Pugliese-Sivo C., Xiao Y., Tagat J.R., Cox K., Priestley T., Sorota S., Huang W., Hirsch M., Reyes G.R., and Baroudy B.M. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49 (2005) 4911-4919
43. Tersmette M., de Goede R.E., Al B.J., Winkel I.N., Gruters R.A., Cuypers H.T., Huisman H.G., and Miedema F. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytiuminducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J. Virol. 62 (1988) 2026-2032
44. Tersmette M., Gruters R.A., de Wolf F., de Goede R.E., Lange J.M., Schellekens P.T., Goudsmit J., Huisman H.G., and Miedema F. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J. Virol. 63 (1989) 2118-2125
45. Trouplin V., Salvatori F., Cappello F., Obry V., Brelot A., Heveker N., Alizon M., Scarlatti G., Clavel F., and Mammano F. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J. Virol. 75 (2001) 251-259
46. Whitcomb J., Huang W., Fransen S., Limoli K., Toma J., Wrin T., Chappey C., Kiss L., Paxinos E.E., and Petropoulos C.J. Development and characterization of a novel single-cycle recombinant virus assay to determine human immunodeficiency virus type-1 Co-receptor tropism. Antimicrob. Agents Chemother. 51 (2006) 566-575